News
As Novo Nordisk works through a period of transition in the U.S. GLP-1 drug market, sales from the company's star obesity ...
Wegovy (semaglutide) could offer a new option to treat severe liver disease based on new clinical trial evidence. The GLP-1 ...
11h
Novo Nordisk Q1 sales missed estimates despite strong growth in Wegovy and Ozempic, prompting a cut to its 2025 guidance amid ...
The FDA in February formally declared the end of the semaglutide shortage, which Novo Nordisk expects will help improve the ...
My doctor said patients have told him they were able to stop drinking and even quit cocaine use while taking Wegovy.
Novo Nordisk is collaborating with multiple telehealth organizations in an effort to increase patient access to authentic ...
Prior to starting the trial, the participants also had moderate to high levels of scar tissue in the liver, known as stage 2 ...
A large trial showed that the weight-loss drug could reduce liver inflammation and scarring caused by the common condition.
Novo Nordisk cut 2025 sales forecast citing competition from compounded versions of its Wegovy weight-loss drug. Invezz takes ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback